[A24-66] Futibatinib (cholangiocarcinoma) – Benefit assessment according to § 35a Social Code Book V
Last updated 22.11.2024
Project no.:
A24-66
Commission:
Commission awarded on 30.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that has progressed after at least one prior line of systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-66_en
| Project no. | Title | Status |
|---|---|---|
| G24-29 | Futibatinib (cholangiocarcinoma) – Addendum to Project A24-66 | Commission completed |
Federal Joint Committee (G-BA)
2024-11-22 A G-BA decision was published.